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Abstract
These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear
Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of
Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain
PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/
guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain
PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino
acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based
medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a
former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), and
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supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET
imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the
context of local conditions and regulations.
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Preamble
The Society of Nuclear Medicine and Molecular Imaging
(SNMMI) is an international scientific and professional organi-
zation founded in 1954 to promote the science, technology, and
practical application of nuclear medicine. Its 18,000 members
are physicians, technologists and scientists specializing in the
research and practice of nuclear medicine. In addition to pub-
lishing journals, newsletters and books, the SNMMI also spon-
sors international meetings and workshops designed to increase
the competencies of nuclear medicine practitioners and to pro-
mote new advances in the science of nuclear medicine. The
European Association of Nuclear Medicine (EANM) is a pro-
fessional nonprofit medical association that facilitates commu-
nication worldwide among individuals pursuing clinical and
research excellence in nuclear medicine, and had 2,800 mem-
bers in 2017. The EANM was founded in 1985.
The SNMMI/EANM will periodically define new
standards/guidelines for nuclear medicine practice to help ad-
vance the science of nuclear medicine and to improve the
quality of service to patients. Existing standards/guidelines
will be reviewed for revision or renewal, as appropriate, on
their fifth anniversary or sooner, if indicated. As of February
2014, the SNMMI guidelines will now be referred to as pro-
cedure standards. Any previous practice guidelines or proce-
dure guidelines that describe how to perform a procedure are
now considered SNMMI procedure standards. Each of the
standards/guidelines, that represents a policy statement by
the SNMMI/EANM, has undergone a thorough consensus
process in which it has been subjected to extensive review.
The SNMMI/EANM recognizes that the safe and effective use
of diagnostic nuclear medicine imaging requires specific train-
ing, skills and techniques, as described in each document.
The EANM and SNMMI have written and approved these
standards/guidelines to promote the use of nuclear medicine
procedures of high quality. These standards/guidelines are
intended to assist practitioners in providing appropriate nucle-
ar medicine care for patients. They are not inflexible rules or
requirements of practice and are not intended, nor should they
be used, to establish a legal standard of care. For these reasons
and those set forth below, the SNMMI/EANM cautions
against the use of these standards/guidelines in litigation in
which the clinical decisions of a practitioner are called into
question.
The ultimate judgment regarding the propriety of any spe-
cific procedure or course of action must be made by medical
professionals taking into account the unique circumstances of
each case. Thus, there is no implication that an approach dif-
fering from the standards/guidelines, standing alone, is below
the standard of care. To the contrary, a conscientious practi-
tioner may responsibly adopt a course of action different from
that set forth in the standards/guidelines when, in the reason-
able judgment of the practitioner, such course of action is
indicated by the condition of the patient, limitations of avail-
able resources, or advances in knowledge or technology sub-
sequent to publication of the standards/guidelines.
The practice of medicine involves not only the science
but also the art of dealing with the prevention, diagnosis,
alleviation and treatment of disease. The variety and com-
plexity of human conditions make it impossible to always
reach the most appropriate diagnosis or to predict with
certainty a particular response to treatment. Therefore, it
should be recognized that adherence to these standards/
guidelines will not ensure an accurate diagnosis or a suc-
cessful outcome. All that should be expected is that the
practitioner will follow a reasonable course of action
based on current knowledge, available resources and the
needs of the patient to deliver effective and safe medical
care. The sole purpose of these standards/guidelines is to
assist practitioners in achieving this objective.
The present guidelines/standards were developed collabo-
ratively by the EANM and SNMMI with the European
Association of Neurooncology (EANO) and the working
group for Response Assessment in Neurooncology with
PET (PET-RANO). They summarize the views of the
Neuroimaging, Oncology and Physics Committees of the
EANM, the Brain Imaging Council of the SNMMI, the
EANO, and PET-RANO, and reflect recommendations for
which the EANM cannot be held responsible. The recommen-
dations should be taken into the context of good practice of
nuclear medicine and do not substitute for national and inter-
national legal or regulatory provisions.
Introduction
Gliomas are the second most common primary brain tumour
with an annual incidence rate of around six cases per 100,000
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individuals worldwide [1]. Gliomas represent approximately
27% of all central nervous system (CNS) tumours and 80% of
malignant CNS tumours, and are a leading cause of cancer
mortality in adults. The most common of all malignant brain
and CNS tumours is glioblastoma (46%) which is associated
with a median overall survival of 15 months in patients treated
with maximal safe tumour resection, concomitant
radiotherapy/chemotherapy and adjuvant chemotherapy [2].
Magnetic resonance imaging (MRI) is the primary clinical
imaging modality in patients with glioma at all disease stages
including the primary evaluation, presurgical planning, early
postsurgical evaluation of residual tumour, radiotherapy plan-
ning, surveillance during chemotherapy, and definition of
recurrence.
There are defined objective and standardized MRI-based
criteria for response assessment in neurooncology (RANO)
applied to clinical trials in patients with brain tumours.
However, MRI contrast enhancement can be unreliable as
a surrogate for tumour size or growth. It nonspecifically
reflects vascular surface area and the permeability of the
contrast agent across a disrupted blood–tumour barrier and
may represent tumour biology or a number of other factors
including therapy-induced inflammation. Contrast enhance-
ment can be influenced by therapeutics that affect tumour
vascular permeability, such as corticosteroid, antiangiogenic
[3] or immunotherapy agents [4]. Because of the growing
awareness of significant limitations of MRI in the manage-
ment of glioma, the RANO criteria were recently updated
[5]. Hence, to identify infiltrative glioma tissue, the RANO
definition of tumour progression was supplemented by in-
clusion of Bsignificant^ enlarging areas of nonenhancing tu-
mour on MRI T2-weighted and fluid-attenuated inversion
recovery (FLAIR) image sequences. However, precise quan-
tification of increases in the T2/FLAIR signal could not be
defined and other causes of increased T2 or FLAIR signal,
such as radiation effects, demyelination, ischaemic injury
and oedema have to be considered in the evaluation of
progression.
Molecular imaging using positron emission tomography
(PET) is a well-established method in systemic oncology
[6], and is being increasingly used to supplement MRI in the
clinical management of glioma [7–9]. PET imaging could
have an important role in clinical trials of new strategies for
the treatment of glioma, e.g. immunotherapy, where
pseudoprogression is particularly challenging for MRI [4].
Recently an evidence-based recommendation by the PET-
RANO working group and EANO on the clinical use of
PET imaging in gliomas has been published focusing on ra-
diotracers used in clinical practice imaging, i.e. glucose me-
tabolism, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), and sys-
tem L amino acid transport comprising [11C-methyl]-methio-
nine (MET),O-(2-[18F]fluoroethyl)-L-tyrosine (FET) and 3,4-
dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA) [7].
The present guidelines/standards focus on the technical as-
pects of PET image acquisition with the above-mentioned
radiotracers, and thus replace all previously published guide-
lines on glioma imaging [10].
Aim
The aim of these standards/guidelines is to assist nuclear med-
icine practitioners in recommending, performing, interpreting,
and reporting the results of brain PET imaging in patients with
glioma.
Definitions
1. PET systems provide static, dynamic or gated images of
the distribution of positron-emitting radionuclides within
the body by detecting pairs of photons produced in coin-
cidence by the annihilation of a positron and an electron.
PET images are produced by a reconstruction process
using the coincidence pair data.
2. PET is generally combined with computed tomography
(CT) in a single system (PET/CT). Combined PET/MRI
systems are also available for clinical use but are currently
less widely available.
3. Nuclear medicine computer systems and software appli-
cations collect, quantitate, analyse and display the imag-
ing information.
Common clinical indications
Common indications for PET imaging in glioma include, but
are not limited to, the following [7]:
1. At primary diagnosis
(a) Differentiation of grade III and IV tumours from
nonneoplastic lesions or grade I and II gliomas
(b) Prognostication of gliomas
(c) Definition of the optimal biopsy site (e.g. site of
maximum tracer uptake)
(d) Delineation of tumour extent for surgery and radio-
therapy planning
2. Diagnosis of tumour recurrence
(a) Differentiation of glioma recurrence from treatment-
induced changes, e.g. pseudoprogression,
radionecrosis
3. Disease and therapy monitoring
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(a) Detection of malignant transformation in grade I and
II gliomas
(b) Response assessment during and after radiotherapy
and/or chemotherapy
(c) Different iat ion of tumour response from
pseudoresponse during antiangiogenic therapy
The performances of the PET tracers presented in this
guideline are different as discussed in a recent evidence-
based recommendation [7].
FDG PET plays a more limited role than amino acid PET in
the imaging of gliomas due to the high physiological uptake of
FDG in normal brain grey matter and variable uptake by in-
flammatory lesions. FDG PET is most often used to distin-
guish tumour recurrence from radiation necrosis in enhancing
brain lesions or to distinguish glioma from CNS lymphoma or
opportunistic infection.
Qualifications and responsibilities
of personnel
Physician PETexaminations should be performed by, or under
the supervision of, a physician specialized in nuclear medicine
and certified by accreditation boards. In Europe, the certified
nuclear medicine physician who performed the study and
signed the report is responsible for the procedure, according
to national laws and rules. In the United States, the SNMMI
Procedure Guideline for General Imaging (Society of Nuclear
Medicine, 2010. http://snmmi.files.cms-plus.com/docs/
General_Imaging_Version_6.0.pdf) should be consulted.
Technologist PET examinations should be performed by a
qualified registered/certified nuclear medicine technologist.
The following documents should be consulted: Performance
Responsibility and Guidelines for Nuclear Medicine
Technologists 3.1 and the EANM Benchmark Document
Nuclear Medicine Technologists’ Competencies (http://
www.eanm.org/content-eanm/uploads/2016/11/EANM_
2017_TC_Benchmark.pdf [11]). In some jurisdictions,
additional qualifications may be necessary for technologists
to operate the CT or MR components.
Physicist PET examinations should be performed using PET
systems that comply with national or international quality
standards (see section Quality control and improvement). A
certified clinical physicist is responsible for ensuring that PET
systems meet these quality standards. Moreover, in some
countries it is required that a board-certified medical physicist
be available to advise the above-mentioned personnel in run-
ning the imaging systems and/or in managing dysfunction or
failure of the systems, and to perform the examinations. In
addition, examinations should be performed following
national or international dosimetry and radiation safety stan-
dards in relation to both patients and personnel.
Examination procedures/specifications
Recommendations for FDG-specific procedures are defined in
previous guidelines, and only recommendations that are new
or particular to glioma are discussed [12, 13].
Request
A nuclear medicine imaging facility staff member should
check with the nuclear pharmacy provider as to the availabil-
ity of the radiotracer before scheduling the examination.
Advanced notice may be required for tracer delivery.
The study requisition should include:
1. Appropriate clinical information about the patient and a
clearly specified clinical question to justify the study and
to allow appropriate examination/study coding (see
section Common clinical indications).
2. Information about the ability of the patient to cooperate
with the examination and the participation of a carer may
be helpful.
3. Information about current medications, including gluco-
corticoids, for correct study interpretation and to avoid
unwanted pharmacological interaction effects if mild se-
dation is necessary.
4. History of prior therapy, including prior chemotherapy,
surgery and radiotherapy, which might affect radiophar-
maceutical distribution.
5. Results of pertinent imaging studies, resections and biop-
sies performed, and laboratory results.
6. For PET/MRI, all patients should be screened at request
for relevant contraindications toMRI using a standardized
checklist (e.g. pregnancy, contrast agent reactions, im-
plants, ports, catheters, metallic implants, vascular stents,
coils, active implants, cardiac pacemakers, claustropho-
bia, etc.) [14].
Patient preparation and precautions
1. The height and body weight of the patient must be docu-
mented for measurement of standardized uptake values
(SUV; see section Static FET, MET, FDOPA PET, item 1).
2. Recent morphological imaging withMRI (T1, T1 + con-
trast medium, T2/FLAIR) should be available for image
fusion.
3. The patient should be informed about the procedure to
guarantee optimal compliance.
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4. The patient should be able to lie down quietly for at least
30 to 40 min.
5. If sedation is required for MET, FET or FDOPA imag-
ing, it should start about 20–60 min before the examina-
tion. If sedation is required for FDG imaging, sedation
should start as late as possible after FDG administration,
ideally at least 30 min after FDG injection but prior to
imaging.
6. The patient should be required to fast before the exami-
nation to ensure stable metabolic conditions. A mini-
mum 4-h fast is recommended for MET, FET, FDOPA,
and FDG imaging.
7. Serum glucose should/may be measured before FDG
administration so that the interpreting physician is aware
of the potential for altered biodistribution.
8. Before scanning, patients should empty their bladder for
maximum comfort during the study and in order to re-
duce the absorbed dose to the bladder (see section
Radiation safety).
9. In pregnant patients, it is necessary to make a clinical
decision that weighs the benefits to the patient against
possible harm [6].
10. For FDOPA PET, premedication with carbidopa is not
necessary. Most published studies to date with FDOPA
PET in patients with brain tumour have not used
carbidopa or other inhibitors of peripheral FDOPA
metabolism.
11. If the PET study is to be acquired as part of a PET/MRI
study:
(a) Check MRI contraindications from checklist (see
section Request, item 6).
(b) Remove all metal from the patient (e.g. dental pros-
theses, clothing with zippers and buttons), and pro-
vide cotton clothing for the patient.
(c) In patients with an implant, the specific type of im-
plant, its location and its component materials need
to be known before anMRI examination. The patient
should be asked for an implant pass. The safety level
of an implant/device should be checked with the
manufacturer (e.g. online): BMRI unsafe^ is an abso-
lute contraindication; BMRI conditional^ is a relative
contraindication, conditions apply; BMRI safe^ is no
contraindication.
(d) If the patient has a metal implant or active device
labelled BMRI conditional^, information should be
obtained about all the conditions that may apply for
safe MRI examination (e.g. from the implant pass or
online).
(e) Beyond safety concerns, implants may cause arte-
facts, large-volume signal voids and geometric dis-
tortions on MRI images. These may hamper image
reading.
12. It is recommended that the patient stay well hydrated and
empty the bladder often.
Radiopharmaceuticals
2-Deoxy-2-[18F]fluoro-D-glucose; fludeoxyglucose F18
(FDG)
O-(2-[18F]Fluoroethyl)-L-tyrosine (FET)
L-[methyl-11C]Methionine; methionine C11 (MET)
3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine;
fluorodopa F18 (FDOPA)
Preparation of radiopharmaceuticals All radiopharmaceuti-
cals must be prepared by qualified personnel according to
cGMP-compliant methods that conform to regulatory require-
ments. The radiopharmaceutical is delivered ready to use.
Quality control (QC) is carried out by the manufacturer prior
to delivery of the final product.
Administered activity in adults The recommended injected
activities for brain imaging in adults are as follows:
18F-FET: 185–200 MBq
11C-MET: 370–555 MBq
18F-FDOPA: 185–200 MBq
18F-FDG: 185–200 MBq
Administered activity in children In children, the radioactivity
dose should be calculated as a fraction of the dose for adults
according to the child’s body weight using the factors provid-
ed by the EANM Paediatric Task Group [15]. The adminis-
tered dose may be reduced in systems with higher sensitivity
(see section Radiation safety).
The above radiopharmaceuticals should be injected as a
bolus.
PET acquisition protocols
Positioning The scan should be performed with the patient
positioned with the head in a dedicated holder and the arms
along the body. The entire brain should be in the field of view,
including the entire cerebellum, and extreme neck extension
or flexion should be avoided.
Head stability
1. The patient should be instructed immediately before the
PETacquisition to avoid head movements during all parts
of the investigation.
2. Head stability can be achieved by positioning the patient
comfortably with the head secured as completely as
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possible in the dedicated holder. Tape, padding or other
flexible head restraints including a thermoplastic mould
and vacuum mattress for children may be employed and
are often helpful particularly for radiotherapy planning.
3. During the entire investigation, the patient should be
continuously visually monitored. Monitoring is partic-
ularly important in patients with tumour-associated
seizures. Seizure activity during the uptake phase of
FDG and FET can lead to increased uptake in the
brain affected by seizure activity and can be mistaken
for tumour.
PET imaging sequence The preferred PET imaging sequence
is:
1. CTscout topogram for PET/CT to set up the field of view.
2. For attenuation correction (see section Attenuation
correction below), a low-dose CT scan, MRI attenua-
tion correction scan or transmission scan should be
performed. Mathematical attenuation correction (i.e.
based on the patient’s external contour (derived from
a PET image without attenuation correction) should
not be applied.
3. Static or dynamic single field of view PET acquisition.
Attenuation correction Images should be acquired in 3D data
acquisition mode and attenuation correction should be based
on a low-dose CT scan, MRI attenuation correction scan, or
511-keV transmission scan. If a 511-keV transmission scan is
used, the transmission images should be acquired before tracer
injection. CT parameters should always be chosen to ensure
the lowest doses that are compatible with this purpose are
administered to the patient.
The following points relevant to attenuation correction in
PET/MRI are to be considered:
1. In PET/MRI, attenuation correction is based on MRI im-
aging. Thus, MRI-based attenuation correction needs to
be accurate and free from artefacts to provide accurate
PET quantification.
2. The latest version of MRI attenuation-correction software
should be used, including ultrashort echo time (UTE),
zero TE (ZTE) sequences, or bone-models for bone de-
tection in brain PET/MRI, where available [16, 17].
3. Various attenuation correction strategies for PET/
MRI have been implemented. Some may lead to sys-
tematic differences in the activity distribution and
calculated semiquantitative metrics (see section
Static FET, MET, FDOPA PET) [18] that should
carefully be considered during interpretation of PET
images [19, 20].
4. MRI attenuation-corrected images must routinely be
checked for artefacts, consistency and plausibility during
PET/MRI reading. Artefacts on MRI attenuation correc-
tion have a direct effect on PET quantification in brain
PET/MRI. Typically artefacts may arise from mis-
segmentation of brain/fat/bone tissue, or from metallic
dental prostheses and metallic implants such as coils,
stents, surgical clips, etc. [18, 21, 22]. Artefacts may show
as signal voids that exceed the true dimensions of the
metal inclusions. Thus, most artefacts are readily detect-
able on MRI attenuation-corrected images and indicate
regions of potentially inaccurate PET quantification [23,
24].
5. Where applicable, time-of-flight PET detection should be
used to reduce the impact of metal artefacts in brain PET/
MRI examinations [25].
6. Only radiofrequency (RF) head coils labelled for com-
bined PET/MRI use only should be used. Using standard
RF head coils labelled for MRI-only use will not be con-
sidered in PET/MRI attenuation correction and their use
may thus lead to inaccurate PET quantification and arte-
facts on PET.
7. In longitudinal studies, the patient should always be
scanned on the same system using the same procedures
to avoid changes related to differences in imaging tech-
nology or methodology. In cross-sectional studies, possi-
ble differences among scans related to the technologies
being used should be considered. Particular care is needed
in paediatric patients.
PET comparability To ensure PET comparability, a standard-
ized protocol for clinical reading should be used with a fixed
time for the start of image acquisition.
1. FET: 20 min static image acquisition obtained
20 min after injection. This may be part of a 40–
50 min dynamic image acquisition initiated at tracer
injection. Dynamic image acquisitions should be
started using short frames that progressively in-
crease in duration. From 10 to 50 min after injec-
tion 5-min acquisition frames should be used to al-
low the tracer uptake slope to be assessed during
this interval. To allow precise information on the
tracer uptake phase to be obtained, the following
image acquisition frame sequences could be used
during the first 10 min after injection: 12 frames
of 5 s, 6 frames of 10 s, 6 frames of 30 s and 5
frames of 60 s.
2. MET: 20 min static image acquisition obtained 10 min
after injection.
3. FDOPA: 10–20min static image acquisition obtained 10–
30 min after injection.
Eur J Nucl Med Mol Imaging (2019) 46:540–557 545
4. FDG: 10–20min static image acquisition obtained at least
45 min after injection.
Movement artefacts If movement artefacts are expected, it
may be helpful to acquire the static time window dynamically,
e.g. in 5-min frames, or in list mode. Check the sinograms, and
use only those of the properly acquired motion-free time pe-
riod for reconstruction.
PET image reconstruction
1. During image reconstruction, all corrections for quantita-
tive interpretation are required including attenuation, scat-
ter, random, dead time and decay corrections, as well as
detector sensitivity normalization.
2. Time of flight acquisitions and reconstructions are
allowed, although the benefit for brain imaging has not
yet been fully investigated.
3. Iterative reconstruction is the field standard and
should be applied. However, if iterative reconstruc-
tion would result in upward bias due to non-
negativity constraints applied during reconstruction,
filtered back-projection reconstruction may be used
as an alternative method.
4. The use of resolution modelling during reconstruc-
tion, so-called point-spread-function (PSF) recon-
structions, may give rise to Gibbs artefacts and quan-
t i ta t ive er rors [26] , and this method is not
recommended.
5. To harmonize PET image quality, the following recon-
struction settings/protocols are recommended:
(a) One of the reconstructions should be performed
using settings such that the reconstructed images
meet EARL requirements for image quality recovery
[6], thereby allowing harmonization of PET data for
multicentre settings or for use with reference
datasets.
(b) As the above harmonizing reconstruction settings
will ensure comparable image quality among differ-
ent generations of PET/CT systems, a higher resolu-
tion reconstruction may be desired or required for
visual interpretation or tumour delineation. When a
specific PET system allows the use of multiple re-
constructions, a high-resolution dedicated brain re-
construction protocol may be applied. Such a proto-
col should preferably meet the following
requirements:
– Voxels size 1–2 mm, but <3 mm in any direction
– Reconstructed spatial resolution <6 mm full-width at
half-maximum
Interpretation/quantification
Standardized uptake value calculations and image analysis
General image display
1. PET images should have pixels of at least 16 bits to pro-
vide an adequate range of values, and appropriate image
scaling should be employed for image display. A colour
scale may be used. PET images should be displayed in the
transaxial orientation and additionally correlated with
morphological images in the coronal and sagittal planes.
2. Internal landmarks can be used for reorientation to
achieve a standardized image display. Reorientation pro-
cedures based on the intercommissural line are commonly
used [27].
3. FET, MET, FDOPA: If the display scale is in colour, it
should be adjusted so that the background radioactivity of
healthy brain is in the lower third of the range (blue hue in
the widely used Sokoloff scale), in order to create stan-
dardized conditions for the visual detection of increased
tracer accumulation above background.
4. FDG: The display scale should be initially adjusted so that
the radioactivity in normal cerebral cortex is near the max-
imum of the scale. If lesions have higher uptake than the
cerebral cortex, the scale should be adjusted such that the
lesion with the highest uptake is near to the maximum of
the scale. Colour scales with 10 or 20 increments are
useful to estimate the relative concentrations of FDG
across brain regions and in lesions.
Static FET, MET, FDOPA PET
1. Calculation of the SUV is optional and may be performed
by dividing the radioactivity concentration (in
kilobecquerels per millilitre) in the tissue by the radioac-
tivity (in megabecquerels) injected per body weight (in
kilograms), body surface area (in metres squared) or lean
body mass (in kilograms), depending on the most appro-
priate distribution volume for each tracer.
2. Standard summation images in the ranges defined in sec-
tion PET comparability (items 1, 2 and 3) are used for
clinical reading and should be coregistered and fused with
recent high-resolution contrast-enhanced T1-weighted,
T2-weighted/FLAIR MRI sequences. Fusion with other
MRI sequences is optional. Usually vendor-provided
coregistration software solutions are sufficiently robust
for clinical use, but must be routinely checked for mis-
alignment during reading. This can be done by adjusting
the PET colour scale to clearly visualize the scalp and
nose of the patient so that these structures can be com-
pared between the PET and MRI images.
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3. In a first visual analysis, qualitative evaluation can be
performed and the lesion of interest can be classified as
either positive, when tracer uptake visually exceeds the
background activity in the contralateral cortex, or
negative, when no increased uptake can be seen.
4. MET, FET: In order to ensure intraindividual as well as
interindividual comparability, semiquantitative measures
of mean and maximal tumour activity uptake values can
be calculated as ratios in relation to healthy appearing
reference brain tissue (tumour to background ratios,
TBRmean and TBRmax, respectively).
(a) The mean physiological brain activity uptake in
healthy appearing cortex of the hemisphere contra-
lateral to the tumour including grey and white matter
is measured from a large Bbanana^/crescent-shaped
background volume of interest (VOI) [28].
(b) The measurement of TBRmean depends on the de-
lineation of the tumour VOI.
5. FDOPA: Semiquantitative measures of mean and maxi-
mal tumour activity uptake values can be calculated as
ratios in relation to healthy appearing striatum [29] con-
tralateral to the tumour (tumour to striatum ratios,
TSRmean and TSRmax, respectively). The striatum is
the most commonly used reference region. Other refer-
ence regions have not been investigated systematically.
Static FDG PET
1. A static image acquired for 10–20 min at least 45 min
after injection is used for clinical FDG PET reading, and
should be coregistered and fused with recent high-
resolution contrast-enhanced T1 and T2/FLAIR MRI se-
quences. Fusion with other MRI sequences is optional.
2. SUVs used directly are generally of limited value in the
clinical interpretation of FDG PET neurooncology
studies.
3. Qualitative visual analysis can be performed and the le-
sion of interest can be classified as either positive, when
FDG uptake visually exceeds the activity in a reference
region (e.g. normal appearing white matter or cerebral
cortex), or negative, when FDG uptake in the lesion is
less than that in the reference region. Using white matter
as the reference region provides better sensitivity for de-
tecting recurrent tumour at the expense of specificity,
while using cerebral cortex provides better specificity at
the expense of sensitivity.
4. Lesion to reference region ratios using mean or maximum
SUV can be used to provide a measure of FDG uptake in
lesions. Numerical cut-off values for distinguishing tu-
mour from benign lesions, such as radiation necrosis,
and for grading tumours are not well established for
FDG. If ratios are used, either white or grey matter rather
than a mixture of the two should be used for reference due
to the substantially higher FDG uptake in greymatter than
in white matter. Additionally, normal-appearing brain
should be considered for the reference region to provide
consistency across studies.
5. The regional metabolic rate of glucose can be estimated in
lesions and normal brain by compartmental modelling or
by using graphical analytical approaches. A correction
factor, the so-called Blumped constant^ [30], can be used
to convert the FDG values to values reflecting glucose
metabolism [31]. However, little is known about the ac-
curacy of these methods in brain tumours and/or treatment
effects. Currently, there is insufficient data to recommend
these types of quantitative studies in routine clinical FDG
PET for neurooncology.
Cut-off thresholds for definition of biological tumour vol-
ume FDG: Not available
FET: SUV >1.6–1.8 of the mean value in healthy
appearing brain (see section Static FET, MET, FDOPA
PET, item 4(a)) [32]
MET: SUV >1.3 of the mean value in healthy appearing
brain [33]
FDOPA: SUV more than the mean value in healthy stri-
atum [29] (not validated histologically)
Dynamic PET acquisition An established clinical value for
dynamic PET acquisitions applies only to FET [7]. Time–
activity curves (TAC), i.e. the mean tissue radioactivity in
the tumour region of interest (ROI)/VOI (SUV; becquerels
per centimetre cubed, counts per centimetre cubed) as a
function of time, can be generated from dynamic FET
PET images. The TAC of the healthy brain (see section
Static FET, MET, FDOPA PET, item 4(a)) should be plot-
ted for comparison to exclude technical artefacts. To ex-
tract the TAC of the most aggressive tumour area and to
provide sufficient count statistics for curve generation, the
following approach is recommended:
1. The VOI is drawn semiautomatically using an individu-
ally adapted isocontour of the tumour maximum yielding
a volume of 1–2 mL, or using a standard ROI/VOI with a
fixed diameter of 1.6 cm centred on the tumour maximum
yielding a volume of 2 mL.
2. These ROIs/VOIs can be defined on the summation im-
ages of 20–40 min or 10–30 min. The latter may be better
suited to the depiction of the early peak uptake in more
aggressive gliomas.
3. The shape of the TAC is classified as increasing, decreas-
ing or plateau. For assessment of time to peak (TTP), the
time of tumour peak uptake is noted.
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Interpretation of static FET/MET/FDOPA PET data Based on
the 2016 WHO classification [34], gliomas will be progres-
sively classified on the basis of histological and molecular
characteristics, rather than as low-grade or high-grade glio-
mas, as follows:
1. Astrocytomas grade II and III (with isocitrate dehydroge-
nase 1 (IDH1) mutation, without 1p/19q codeletion) [35]
2. Oligodendrogliomas grade II and III (with IDH1 muta-
tion, with 1p/19q codeletion) [36]
3. Wildtype astrocytomas or oligodendrogliomas not other-
wise specified
4. Secondary glioblastomas (with IDH1 mutation)
5. Primary glioblastomas (IDH1 wildtype or IDH1-
negative) [37, 38]
Available data on the range of radiotracer uptake are limited
to FDG, FET and MET [39–43]. Further evidence is required
to complement molecular characterization of gliomas and im-
plement radiotracers in the new classification.
1. At primary diagnosis
(a) Negative scan: uptake in the background uptake
range or slightly above excludes a grade III/IV glio-
ma, lymphoma or metastasis with high probability.
Also, an oligodendroglial tumour is very unlikely. A
grade I/II astrocytoma cannot be excluded since ap-
proximately 30% exhibit low uptake.
(b) Positive scan: increased uptake has high a positive
predictive value for a neoplastic process. A reliable
differentiation of grade III/IV and grade I/II gliomas
is not possible because of a high proportion of active
tumours among the la t t e r, e spec ia l ly in
oligodendrogliomas. Local areas with the highest
uptake should be used for biopsy guidance.
2. Therapy planning: for FET and MET, areas with uptake
higher than the above biological tumour volume (BTV)
cut-off activity values are used to delineate the metaboli-
cally active tumour tissue for planning of surgery and
radiotherapy.
3. Tumour recurrence: increased uptake in the follow-up of
previously treated glioma has high accuracy in differenti-
ating treatment-related changes (e.g. pseudoprogression,
radionecrosis) from recurrent disease.
4. Therapy monitoring: amino acid uptake progression dur-
ing different kinds of therapy is indicative of therapy fail-
ure, while uptake regression indicates responsiveness.
FET and FDOPA PET have been shown to identify
pseudoresponse during antiangiogenic therapy.
The TBRmean and TBRmax thresholds for establishing
pathological amino acid accumulation depends on the ROI
definition technique, the spatial resolution of the PET scan
(system type, reconstruction, data filtering) and the clinical
question to be answered [44]. The thresholds according to
clinical questions are shown in Table 1.
Interpretation of static FDG PET data
1. At primary diagnosis
(a) Increasing FDG uptake by gliomas is correlated with
higher grade and worse prognosis [7, 61–64]. Grade
I/II gliomas typically have FDG uptake similar to or
less than white matter uptake, although some grade
I/II gliomas such as pilocytic astrocytomas have high
FDG uptake. Grade III/IV gliomas typically have
FDG uptake greater than white matter uptake (see
comments on the new WHO classification scheme
(see section Interpretation of static FET/MET/
FDOPA PET data, item 1).
(b) There is overlap in FDG uptake between grade I/II
and grade III/IV gliomas, particularly for gliomas
with FDG uptake greater than white matter but less
than greymatter uptake. Optimal quantitative thresh-
olds and visual analysis criteria have not been
established for definitively distinguishing glioma
grade or predicting prognosis based on FDG PET
alone.
2. Tumour recurrence
(a) High FDG uptake in enhancing brain lesions is cor-
related with tumour recurrence. However, high FDG
uptake can occur in the brain after radiation therapy
including radiation necrosis, and recurrent tumours
may have relatively low FDG uptake. Well-defined
quantitative and qualitative criteria with high diag-
nostic accuracy are not available and may not be
achievable with FDG PET.
(b) For gliomas treated with radiation therapy, FDGPET
can be used to distinguish radiation necrosis from
recurrent tumour. Many criteria have been proposed,
and wide ranges of sensitivity and specificity have
been reported in the literature [65–71]. A reasonable
approach is to use normal white and grey matter as
the reference regions. Lesions with FDG uptake sim-
ilar to or less than white matter uptake are probably
radiation necrosis while lesions with FDG uptake
higher than grey matter uptake are probably recur-
rent tumour. Lesions with FDG uptake higher than
white matter but less than grey matter uptake may be
radiation necrosis, recurrent tumour or a mixture of
both. Correlation with MRI, the presence of focal
uptake suggesting recurrence within a larger region
of diffuse lower level FDG uptake, and the clinical
presentation may be useful in these cases.
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(c) The choice of the quantitative cut-off value or visual
reference region will affect the sensitivity and spec-
ificity of the results. For example, using normal
white matter as the reference region and categorizing
lesion with FDG uptake similar to or less than white
matter uptake as radiation necrosis and lesions with
uptake higher than normal white matter uptake as
recurrent tumour will provide higher sensitivity (neg-
ative imaging more likely to be treatment effect) at
the expense of specificity (positive imaging more
likely to be false positive). Similarly, using normal
grey matter as the reference region will provide low-
er sensitivity (negative imaging more likely to be
false-negative) with an increase in specificity (posi-
tive imaging more likely to be recurrent tumour).
Interpretation of dynamic FET PET data
1. An early peak in the TAC shape of the mean ROI/VOI
activity (<20 min after injection) followed by a plateau or
a decreasing TAC is indicative of a grade III/IV tumour.
2. Continuously increasing uptake up to 40 min after injec-
tion is more frequently observed in grade I/II gliomas, but
is not specific. This TAC pattern is also typical of
treatment-induced changes, e.g. radionecrosis,
pseudoprogression.
3. A change in the TAC pattern during follow-up of grade
I/II gliomas from an increasing TAC to an early peak with
a decreasing TAC is indicative of malignant transforma-
tion [54].
Physiological tracer distribution FDG
1. Common: high physiological uptake in grey matter
(e.g. cerebral and cerebellar cortex, deep grey nuclei).
2. Common: moderate uptake in the extraocular
muscles.
3. Occasionally: brain activation during the uptake
phase such as patient motion or visual stimulation
can result in higher uptake in the associated regions
in the cerebral cortex.
FET, MET [72]
1. Common: slight uptake in vascular structures, basal
ganglia, cerebellum, skin and salivary glands.
Table 1 Commonly used thresholds for amino acid PET, validated histologically or clinically, according to the clinical question
Clinical question Tracer Method Threshold Reference
Differentiation between neoplastic and non-neoplastic tissue FET TBRmax 2.5 [45]
TBRmean 1.9
MET TBRmax 1.3–1.5 [33, 46]
FDOPA – n.a.
Tumour grading (grade I/II versus III/IV glioma) FET TBRmean 1.9–2.0 [45, 47,
48]TBRmax 2.5–2.7
TTP <35 min
TAC pattern (I, II, III) Pattern II, III
Tumour extent FET TBR 1.6 [32]
MET TBR 1.3 [49]
FDOPA TBR 2.0 [50]
Tumour recurrence FET TBRmean (circular ROI diameter 1.6 cm) 2.0 [51]
TTP <45 min
MET TBRmax 1.6 [52]
FDOPA TSRmax 2.1 [53]
TSRmean 1.8
Malignant transformation of grade I/II glioma FET TBRmax >33% increase [54]
TBRmean >13% increase
TTP change in ROI >1.6 brain 6 min decrease
Differentiation between early pseudoprogression and true
progression
FET TBRmax 2.3 [55]
Differentiation between late pseudoprogression and true
progression
FET TBRmax 1.9 [56]
TBRmean 1.9
Identification of responders in treatment response evaluation FET Radiochemotherapy (7–10 days) TBRmax >20% decrease [57–59]
TBRmean >5% decrease
Bevacizumab/irinotecan
(4–12 weeks)
BTV >45% decrease
MET Temozolomide TBRmax Stable or
decreasing
[60]
FDOPA Bevacizumab (2 weeks) BTV >35% decrease [29]
<18 mL
TBR tumour to background ratio, TTP time to peak, TAC time–activity curve, TSR tumour to striatum ratio, ROI region of interest
Eur J Nucl Med Mol Imaging (2019) 46:540–557 549
2. Occasionally: slight focal uptake in pineal body, cho-
roid plexus and clivus bone marrow.
FDOPA
1. Common: moderately increased uptake in basal gan-
glia and pituitary, and slight uptake in the cerebellum,
skin, optic nerve, ocular muscles and salivary glands.
2. Occasionally: pineal body.
3. No increased uptake in vascular structures.
Known pitfalls All tracers
1. Uptake may be increased in inflammatory lesions and
epileptic seizures.
2. Uptake may be underestimated in small lesions rela-
tive to image resolution.
FDG
1. High uptake in grey matter can obscure lesions within
or adjacent to grey matter.
2. High blood glucose levels at the time of injection
decrease uptake in tumour and healthy appearing grey
matter, but may not affect lesion detection.
3. Perivascular infiltration.
4. Anatomical abnormalities.
5. Treatment effects may decrease uptake in the treat-
ment area and brain regions that receive synaptic in-
put from the treated area (diaschisis).
MET, FET, FDOPA
1. TBRmean, TBRmax and BTV may be overestimated
if there is reduced uptake in the reference brain tissue
VOI because of structural changes, e.g. atrophy, trau-
ma and infarcts, or reduced tracer delivery. e.g.
ischaemia.
2. As MET, FET, and FDOPA are all transported across
the blood–brain barrier and into cells by system L
amino acid transport, they can all be expected to have
similar pitfalls (Table 2).
Dynamic FET
1. In early images, up to 15 min after injection, blood
pool uptake is relatively high, and tracer activity in
vascular structures may have the same appearance as
tumour tissue uptake.
2. Reduced uptake in occipital and temporal skin areas
may be seen in static images, probably as a result of
reduced perfusion caused by the head padding.
3. An increasing TAC may indicate inflammatory
lesions.
4. A decreasing TAC may be seen in WHO grade II
oligodendroglial tumours (around 50%).
5. A decreasing TAC may be seen in tumours close to
sinuses because of the influence of venous blood
activity.
6. After antiangiogenic treatment the TAC may change
from a decreasing to an increasing pattern.
Documentation and reporting
Description of findings in brain tumour imaging should gen-
erally comply with previously published guidelines for FDG
imaging in oncology and with regard to general aspects of
reporting such as due diligence [6].
The content of the report affects patient management and
clinical outcomes, and is a legal document. It is good practice
to provide a structured report with concise concluding state-
ments intended to answer the specific clinical question(s)
posed, if possible.
Regardless of the radiotracer, reports should follow the
general structure outlined below.
General information 1. Name of the patient and other iden-
tifiers, such as date of birth.
2. Name of the referring physician.
3. Type and date of examination.
4. Radiopharmaceutical including route of administration
and amount of activity administered.
5. Patient history with emphasis on diagnosis and tumour-
related treatment and the clinical question leading to the
study request (see sections Common clinical indications
and Request).
Body of the report 1. Procedure description
(a) Information on the imaging procedure (e.g. static or
dynamic scan), and time between PET tracer injec-
tion and image acquisition.
(b) If FDG is used, the measured blood glucose level at
the time of injection.
(c) If sedation is performed, type and time of medication
in relation to the tracer injection.
(d) If a low-dose CT scan is performed for attenuation
correction, a statement such as Bnot performed for
diagnostic purposes, not replacing diagnostic CT^
could be added.
(e) The use of a nonconventional system type (e.g. PET/
MRI) should be mentioned.
2. Data quality
(a) Abnormal tracer biodistribution.
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(b) CT-related artefacts, e.g. from metallic implants.
(c) Poor compliance with fasting.
(d) Any observed events that may adversely influence
interpretation, e.g. head movements, seizure activity.
(e) If FDG is used, increased blood glucose level.
3. Comparative data
(a) PET images should be comparedwithmorphological
data, particular MRI data, whenever possible.
(b) PET images should be compared with previous PET
scans to evaluate the course of disease.
(c) The type and date of comparative data should be
noted before description of the imaging findings.
4. Description of findings
(a) The normality of radiotracer uptake should be stated,
whether normal or abnormal.
(b) In case of abnormal findings, the location (with a
correct anatomical description), extent and intensity
of pathological tracer accumulation in relation to
normal tissue uptake should be described.
(c) Uptake characteristics, including:
– Shape of uptake, e.g. focal, diffuse, inhomogeneous.
– Intensity of uptake in relation to healthy brain uptake
(slight, moderate or strong).
– Extent and peak uptake, in correlation with, for example,
T1 con t ras t enhancemen t and /o r T2 /FLAIR
hyperintensity on MRI or obvious anatomical abnormal-
ities on CT/low-dose CT images.
(d) Semiquantitative parameters
– Calculate and report the TBRmax. Reporting the
TBRmean and BTV is optional. Determination of
FDG SUV/SUV ratio, TBRmean, TBRmax and
BTV are optional in the clinical setting and do not
have well-established utility in characterizing glio-
mas or distinguishing treatment effects from
recurrence.
– When dynamic imaging is performed with FET, the pat-
tern of the tumour TAC (increasing, decreasing, plateau)
should be described. The reporting of TTP and slope is
optional.
(e) Clinically relevant incidental findings should be re-
ported, e.g. extracerebral metastases.
(f) Comparison with previously performed PET studies,
e . g . f o r t h e r apy r e spons e o r ma l i gnan t
transformation.
5. Limitations:
when appropriate, factors that could have limited data
quality or diagnostic accuracy should be mentioned
(Table 2).
Table 2 Known pitfalls and estimated occurrence of false-positive presentation in amino acid PET and FDG PET
Condition Tracer Estimated occurrence of false positive presentation Reference
Brain abscess, infection, inflammation MET Rare [73]
FET Rare [58, 74, 75]
FDG Variable [76]
Haematoma MET Increased uptake up to 45 days after bleeding [46, 77, 78]
FET Increased uptake up to 14 days after bleeding [79]
FDG Increased uptake up to 4 days after bleeding [80]
Infarction MET [46, 81]
FET Increased uptake up to 7 days after ischaemia [58, 82]
FDG Increased uptake up to 14 days after ischaemia [80]
Developmental venous anomalies FET Rare [83]
FDOPA [58, 82, 84]
Demyelination MET Rare [33, 46]
FET [58, 74]
FDG [85]
Radionecrosis/radiation-induced changes MET Rare [86]
FET Higher incidence of PET-positive findings in
radiation-induced lesions during the first 6 months
after focused high-dose radiotherapy
[87]
FDG Variable [65]
Epileptic seizures FET Very rare [88]
MET [89]
FDG Rare [90]
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Interpretation The interpretation should address the question
raised in the clinical request and integrate medical history,
comparative imaging and any limitations. A precise diagnosis
should be given whenever possible. Additional scans or
follow-up scans should be recommended when appropriate.
Equipment specifications
System specifications
The use of state-of-the-art 3D PET/CT or PET/MRI systems is
recommended. The system should allow collection of low-dose
CT images or MRI-based sequences that can be used for atten-
uation and scatter correction of the PET emission data. A dedi-
cated brain PET-only system may be used provided it is
equipped with transmission scan sources of sufficient strength
– as recommended by the manufacturer – to ensure sufficient
quality of the transmission scans and thereby of the PET emis-
sion data attenuation correction. PET(/CT) systems should have
a minimal axial field of view of 15 cm to ensure sufficient
coverage of the entire brain, including cerebellum and brainstem.
PET acquisition
The system should be able to acquire both static and dynamic
or list-mode PET emission data in 3D mode. Data should be
reconstructed online or offline (i.e. retrospectively) in single
or multiple frames, as specified by the study protocols and
these guidelines. In addition, PET images should be able to
be reconstructed with and without attenuation correction. The
PET images without attenuation correction should not be used
for primary interpretation but can be useful for recognizing
attenuation artefacts in the attenuation-corrected PET images.
The system should have all functionalities and methods avail-
able as required for quantitative brain PET imaging and recon-
struction, including, but not limited to, online randoms correc-
tion, scatter correction, attenuation correction, dead time cor-
rection, decay and abundance correction and normalization
(correction for detector sensitivities).
Quality control and improvement
Quality control and interinstitutional PET system
performance harmonization
Various factors affecting PET image quality and quantification
have previously been reviewed [91]. Although this review
focused on the use of radiolabelled amino acids and FDG
for glioma imaging, the technical and imaging physics uncer-
tainties indicated in that review are valid for any PET exami-
nation regardless of radiotracer or specific application. The
use of brain PET examinations in multicentre studies and/or
when data are compared with a reference database or disease
pattern, it is of the utmost importance that PET data are col-
lected in such a manner that they can be pooled and compared.
In order to guarantee sufficient image quality, quantitative
performance and image harmonization, the performance of
the PET systems must be regularly checked by several QC
experiments. All regular and vendor-provided maintenance
and QC procedures should be followed. QC experiments
should at least address the following:
& Daily check of detector performance, i.e. with point, rod or
cylindrical sources to automatically test and visualize the
proper functioning of detector modules including inspec-
tion of 2D sinograms.
& Daily check of PET activity concentration measurement
calibration using an activity filled cylindrical phantom
source following the procedure recommended by the
manufacturer.
& Cross-calibration of the PET(/CT) system against the lo-
cally used dose calibrator to prepare and measure patient-
specific radiotracer activities. Cross-calibrations should be
performed following EARL recommendations and criteria.
& Correct alignment between PETand CTshould be verified
according to the procedure and frequency recommended
by the manufacturer.
& Additional QC procedures performed less frequently fol-
lowing the instructions provided by the manufacturer and
the EANM recommendations for routine QC of nuclear
medicine equipment [92].
CT quality control
The EU guidelines for FDG PET/CT tumour imaging discuss
several documents and reports that have been published on CT
quality control (CT-QC). For example, an overview of CT-QC is
given in the BEquipment Specifications^ and BQuality Control^
sections of the following American College of Radiology
(ACR) practice parameters: BACR–ASNR–SPR Practice pa-
rameter for the performance of Computed Tomography (CT)
of the extracranial head and neck^ (https://www.acr.org/-/
media/ACR/Files/Practice-Parameters/CT-Head-Neck.pdf?la=
en), BACR–SCBT-MR–SPR–STR Practice parameter for the
performance of thoracic computed tomography (CT)^ (https://
www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-
Thoracic.pdf?la=en), and BACR–SPR Practice parameter for the
performance of thoracic Computed Tomography (CT) of the
abdomen and Computed Tomography (CT) of the Pelvis^,
(https://www.acr.org/-/media/ACR/Files/Practice-Parameters/
CT-Abd-Pel.pdf?la=en). CT-QC is also the subject of the
Institute of Physics and Engineering in Medicine (IPEM) report
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Testing of Diagnostic X-Ray Systems^. In addition, CT perfor-
mance monitoring guidelines are given in the American College
of Radiology: ^ACR–AAPMTechnical standards for diagnostic
medical physics performance monitoring of Computed
Tomography (CT) Equipment^, (https://www.acr.org/-/media/
ACR/Files/Practice-Parameters/CT-Equip.pdf?la=en).
MR quality control in PET/MRI
While there are no regulatory requirements for special/standard
QC/QA procedures for MRI systems, numerous points should
be considered for conducting safe and high-quality MRI exam-
inations as outlined in section Examination procedures/specifi-
cations. It is advisable to adhere to the recommendations of the
manufacturer (i.e. follow the plannedmaintenance intervals). For
PET/MRI systems an approach to basic MRI QC to be per-
formed by the user is described in a review by Sattler et al. [93].
Radiation safety
The systemic use of radiotracers leads to systemic exposure of
the patients to radiation. The amounts of radioactivity usually
delivered with the administration of 11C-labelled and 18F-la-
belled PET radioligands (see section Administered activity in
adults) result in effective doses (ED) of the same order of
magnitude as delivered by other 11C-labelled and 18F-labelled
radiotracers [94]. The radiation dose from low-dose CT scans
of the head region depends on the CTscanning parameters and
is generally well below 0.5 mSv. The overall ED from PET/
CT investigations of the head region, when accounting for the
whole-body exposure, should remain near or below 5 mSv. In
adults, the organ with the highest radiation dose for all the
above tracers is the urinary bladder wall (Table 3).
Conclusion
Since the previous EANMguidelines in 2006 [10], the clinical
use of molecular imaging with PET and PET/CT in the diag-
nosis of glioma has continuously increased in Europe and the
US. For successful and appropriate use of this technology, a
clear understanding of the capabilities and limitations of the
technology and appropriate patient selection, preparation,
scan acquisition and image reconstruction are required. This
document attempts to provide some guidance on the perfor-
mance and interpretation of molecular imaging to supplement
recent clinical guidelines [7], and to bring PET brain imaging
into daily clinical practice and into larger scale interinstitution-
al clinical neurooncological trials across imaging platforms.
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Table 3 Radiation dosimetry
Radiotracer Adult organ with highest dose (mGy/MBq) Effective dose (mSv/MBq) Reference
Adult Paediatric
18F-FDG Urinary bladder wall: 0.13 0.019 1 year: 0.095
5 years: 0.056
10 years: 0.037
15 years: 0.024
[95]
18F-FET Urinary bladder wall: 0.085 0.016 1 year: 0.082
5 years: 0.047
10 years: 0.031
15 years: 0.021
[95]
11C-MET Urinary bladder wall: 0.092 0.0082 1 year: 0.047
5 years: 0.025
10 years: 0.016
15 years: 0.011
[95]
18F-FDOPA Urinary bladder wall: 0.30 0.025 1 year: 0.10
5 years: 0.07
10 years: 0.049
15 years: 0.032
[95]
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